Recombinant Human CD83 Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CD83 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by the ability of the immobilized protein to support the adhesion of human monocyte-derived dendritic cells. When 5 x 10⁴ cells/well are added to human CD83/Fc Chimera coated plates (5 µg/mL, 100 µL/well), approximately 50-75% will adhere after 30 minutes at 37° C.
  Optimal dilutions should be determined by each laboratory for each application.
• Source: Spodoptera frugiperda, Sf 21 (baculovirus)-derived human CD83 protein
  

  Human CD83 (Thr20 - Ala143) Accession #Q01151	DIEGRMD	Human IgG1 (Pro100 - Lys330)
  N-terminus		C-terminus

• Accession #: Q01151
• N-terminal Sequence: Thr20
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: CD83
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.01 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 40.7 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 51-54 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD83 Fc Chimera Protein, CF

• B-cell activation protein
• BL11
• BL11CD83 antigen
• CD83 antigen (activated B lymphocytes, immunoglobulin superfamily)
• CD83 molecule
• CD83
• Cell surface protein HB15
• cell-surface glycoprotein
• HB15
• HB15hCD83

Background

Human CD83 is a 40 - 50 kDa member of the Siglec (or sialic-acid-binding immunoglobulin-like lectin) family of transmembrane proteins (1, 2, 3). CD83 is synthesized as a type I transmembrane glycoprotein that contains a 125 amino acid (aa) extracellular region, a 22 aa transmembrane segment, and 39 aa cytoplasmic domain . It contains one V type Ig-like domain in the extracellular region with no inhibitory cytoplasmic motif(s). Although in vitro studies suggest CD83 may form membrane-bound covalent homodimers, in vivo this does not appear to be the case (1, 4). In the extracellular region, mouse and human CD83 are 66% aa identical (1, 2, 4, 5). Relative to human, mouse CD83 is 11 aa shorter in its extracellular domain and is expressed as a 30 - 35 kDa protein (1, 4, 5). Human CD83 is active in the mouse system (4). One alternate splice form has been reported. This leads to a small monomeric soluble form of 74 aa that includes aa’s # 20 - 52 and # 164 - 205 (6, 7). In human, proteolytic cleavage and solubilization of CD83 has also been suggested, and this could lead to dimeric circulating CD83 (4, 6). CD83 is a primary marker for dendritic cells (3, 6, 8). It is also found on B cells (6, 9), neutrophils (10), monocytes and macrophages (11). Except for dendritic cells, CD83 expression is often transient. CD83 binds to sialic acids on target cells (12). The function of CD83 is only now becoming clear. Membrane CD83 appears to promote T cell proliferation, particularly of CD8⁺ cytotoxic T cells (13, 14). Soluble CD83, however, appears to be immunosuppressive and blocks T cell activation (15, 16). On monocytes, CD83 is suggested to drive monocytes into a fibrocyte phenotype (13). A lack of membrane-expressed CD83 leads to an unusual IL-4/IL-10 producing CD4⁺ T cell phenotype (17).

1. Zhou, L-J. et al. (1992) J. Immunol. 149:735.
2. Kozlow, E.J. et al. (1993) Blood 81:454.
3. Fujimoto, Y and T.F. Tedder (2006) J. Med. Dent. Sci. 53:85.
4. Lechmann, M. et al. (2005) Biochem. Biophys. Res. Commun. 329:132.
5. Berchtold, S. et. al. (1999) FEBS Lett. 461:211.
6. Hock, B.D. et al. (2001) Int. Immunol. 13:959.
7. Dudziak, D. et al. (2005) J. Immunol. 174:6672.
8. Velten, F.W. et al. (2007) Mol. Immunol. 44:1544.
9. Cramer, S.O. et al. (2000) Int. Immunol. 12:1347.
10. Yamashiro, S. et al. (2000) Blood 96:3958.
11. Cao, W. et al. (2005) Biochem. J. 385:85.
12. Scholler, N. et al. (2001) J. Immunol. 166:3865.
13. Scholler, N. et al. (2002) J. Immunol. 168:2599.
14. Hirano, N. et al. (2006) Blood 107:1528.
15. Kotzor, N. et al. (2004) Immunobiology 209:129.
16. Zinser, E. et al. (2006) Immunobiology 211:449.
17. Garcia-Martinez, L.F. et al. (2004) J. Immunol. 173:2995.

Bioinformatics

• Gene Symbol: CD83
• Uniprot:
  • Q01151()